Why Vera Therapeutics Stock Crushed it Today

VERA +13.25%

Key Points

• An analyst expressed his very bullish view on the biotech in a new research note.

• He reiterated his equivalent of a buy recommendation, and his lofty price target.

• 10 stocks we like better than Vera Therapeutics ›

Vera Therapeutics (NASDAQ: VERA) was a standout in the biotech sector on Wednesday. Its stock closed that trading session 13% higher, thanks in no small part to a bullish new note published by an analyst that morning.

A huge potential market

The prognosticator behind the positive note was Cantor Fitzgerald's Pete Stavropoulos, who reiterated his existing overweight (read: buy) recommendation and $100 per share price target on Vera's stock. Even after Wednesday's rise, that level is more than three times the company's current share price.

According to reports, Stavropoulos believes Vera is still loaded with potential due to the company's progress in developing a treatment for IgA Nephropathy (IgAN; also known as Berger's disease), a serious kidney ailment that can lead to organ failure.

The analyst believes IgAN is a potentially multi-billion-dollar market, so if Vera successfully brings a drug to pharmacy shelves, it could earn significant revenue. In his estimation, the patient population of the U.S. ranges from 85,000 to 151,000 individuals.

Promising development

As ever with biotechs, I must caution that buying them is always risky -- after all, they tend to be boom-or-bust investments dependent on their development cycles. With that in mind, Vera appears to have above-average chances, given that the IgAN program has progressed significantly and the addressable market is substantial.

Should you invest $1,000 in Vera Therapeutics right now?

Before you buy stock in Vera Therapeutics, consider this:

The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Vera Therapeutics wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.

Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $563,022!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,090,012!*

Now, it’s worth noting Stock Advisor’s total average return is 991% — a market-crushing outperformance compared to 192% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.

See the 10 stocks »

*Stock Advisor returns as of November 24, 2025

Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Why Vera Therapeutics Stock Crushed it Today was originally published by The Motley Fool